Crewe Advisors’s 4D Molecular Therapeutics FDMT Stock Holding History

Crewe Advisors’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-142	Closed	-$2.44K	–	928
2023 Q1	$2.44K	Hold	142	–	–	﹤0.01%	705
2022 Q4	$3.15K	Hold	142	–	–	﹤0.01%	761
2022 Q3	$1K	Hold	142	–	–	﹤0.01%	1140
2022 Q2	$1K	Buy	+142	New	+$1.38K	﹤0.01%	1062

Other funds holding FDMT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Crewe Advisors's FDMT Position: Q2 2023 in Review

Crewe Advisors sold out of 4D Molecular Therapeutics (FDMT) in Q2 2023, closing a stake of 142 shares — an estimated $2.44K sold.

Crewe Advisors first reported a position in FDMT in Q2 2022 and held it in 4 quarters. The position peaked at $3.15K in Q4 2022. 100 funds tracked by Wall St. Rank hold FDMT as of Q2 2023.

Crewe Advisors reported no remaining 4D Molecular Therapeutics position as of Q2 2023 after selling out during the quarter.
Crewe Advisors sold 142 4D Molecular Therapeutics shares in Q2 2023, an estimated $2.44K.
Crewe Advisors first reported a position in 4D Molecular Therapeutics in Q2 2022 and held it in 4 quarters.
Crewe Advisors's 4D Molecular Therapeutics position peaked at $3.15K in Q4 2022.
100 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2023.

Based on Crewe Advisors's 13F filing for Q2 2023, filed 28 Jul 2023.